search
Back to results

Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
CHF 5188 pMDI
Budesonide extrafine pMDI
Seretide(r) Evohaler(r)
Sponsored by
Chiesi Farmaceutici S.p.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Moderate or severe asthma partly controlled with ICS or ICS/LABA
  • FEV1 ≥ 60% and ≤ 90% of predicted for the patient normal value

Exclusion Criteria:

  • Diagnosis of COPD
  • History or current evidence of significant cardiovascular disease
  • Uncontrolled concomitant disease

Sites / Locations

  • The Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

CHF 5188 pMDI

Budesonide extrafine pMDI

Seretide(r) Evohaler(r)

Arm Description

Outcomes

Primary Outcome Measures

Trough FEV1 (mean 23h-24h FEV1)

Secondary Outcome Measures

Trough FEV1 and forced vital capacity (FVC) (mean 23h-24h)
Trough FVC (mean 23-24h)
Peak FEV1 and FVC
FEV1 AUC0-24

Full Information

First Posted
February 17, 2010
Last Updated
March 28, 2017
Sponsor
Chiesi Farmaceutici S.p.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT01070524
Brief Title
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Official Title
A Randomised, Double-blind, Active-controlled, 3 Way Cross-over Study to Evaluate the Effect on Trough FEV1 After 4 Weeks Treatment With CHF 5188 pMDI qd (Fixed Combination Budesonide / Carmoterol) in Adult Patients With Moderate or Severe Persistent Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Chiesi Farmaceutici S.p.A.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma
Detailed Description
A randomised, double-blind, multinational, multicentre, active-controlled, 3-way cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with moderate or severe persistent asthma

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
113 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CHF 5188 pMDI
Arm Type
Experimental
Arm Title
Budesonide extrafine pMDI
Arm Type
Active Comparator
Arm Title
Seretide(r) Evohaler(r)
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
CHF 5188 pMDI
Intervention Description
CHF 5188: fixed combination budesonide/carmoterol
Intervention Type
Drug
Intervention Name(s)
Budesonide extrafine pMDI
Intervention Description
Budesonide extrafine pMDI
Intervention Type
Drug
Intervention Name(s)
Seretide(r) Evohaler(r)
Intervention Description
Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
Primary Outcome Measure Information:
Title
Trough FEV1 (mean 23h-24h FEV1)
Time Frame
after day 28 dose
Secondary Outcome Measure Information:
Title
Trough FEV1 and forced vital capacity (FVC) (mean 23h-24h)
Time Frame
after day 1 dose
Title
Trough FVC (mean 23-24h)
Time Frame
after day 28 dose
Title
Peak FEV1 and FVC
Time Frame
on day 1 and day 28
Title
FEV1 AUC0-24
Time Frame
after day 1 and day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Moderate or severe asthma partly controlled with ICS or ICS/LABA FEV1 ≥ 60% and ≤ 90% of predicted for the patient normal value Exclusion Criteria: Diagnosis of COPD History or current evidence of significant cardiovascular disease Uncontrolled concomitant disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dave Singh, MD
Organizational Affiliation
The Medicines Evaluation Unit Ltd
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road
City
Manchester
ZIP/Postal Code
M23 9QZ
Country
United Kingdom

12. IPD Sharing Statement

Links:
URL
https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013759-32
Description
Study Record on EU Clinical Trials Register including results

Learn more about this trial

Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma

We'll reach out to this number within 24 hrs